Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May 1;28(5):602-607.
doi: 10.4103/njcp.njcp_499_24. Epub 2025 Jun 4.

Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study

D Sahin  1 , N Soyer  2 , M Yeral  3 , S Namdaroglu  4 , F Hindilerden  5 , I Aydogdu  6 , Hba Ozturk  1 , B Turgut  7 , O Bilgir  8 , M S Dal  9 , A Gunes  2 , M H Dogu  10 , S Demircioglu  11 , A Tombak  12 , F Vural  2 , E Gulturk  5 , S Korkmaz  13 , T Ulas  9 , B Eser  14 , F Altuntas  9   15
Affiliations
Free article
Multicenter Study

Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study

D Sahin et al. Niger J Clin Pract. .
Free article

Abstract

Background: Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), or nasal NK/T-cell lymphoma is the most common cause of the syndrome known as "fatal midline granuloma."

Aim: In this study, we aimed to analyze the treatment outcomes of extranodal natural killer (NK)/T-cell lymphomas.

Methods: Data of 39 patients from 15 centers were evaluated retrospectively. The characteristics that determine the risk status of the patients, in which treatments they received, and their responses were observed.

Results: Complete response was achieved in 21 patients (53.8%) who received first-line therapy. Median follow-up was 12.5 months (range, 1-60 months) and mortality was 56.4% in patients with highly advanced disease. Median overall survival was 16 (95% CI, 13.07-18.93) months.

Conclusion: The prognosis of patients with ENKL has been improved with the use of anthracycline-free treatments, but mortality rates remain high in advanced patients.

Keywords: Natural killer/T-cell lymphoma; SMILE; prognosis; treatment outcome.

PubMed Disclaimer

References

REFERENCES

    1. Salcedo LMJ, Conde Royo D, Dalia S. Extranodal NK/T-cell lymphoma, nasal type (ENKL). Atlas Genet Cytogenet Oncol Haematol 2019;23:146–8. doi: 10.4267/2042/70457.
    1. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005;130:860–8. doi: 10.1111/j. 1365-2141.2005.05694.x.
    1. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009;20:110–6. doi: 10.1093/annonc/mdn542.
    1. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016–20. doi: 10.1111/j. 1349-7006.2008.00768.x.
    1. Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003;78:163–7. doi: 10.1007/BF02983387.

Publication types

LinkOut - more resources